nemtabrutinib
Small moleculeexperimental
Clinical trial activity
19 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03162536)
Timeline
Indications
Studied for
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 2
- Leukemia, B-Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Liver Diseases · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Squamous Intraepithelial Lesions · Phase 3
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccc(Oc2ccccc2)cc1Cl)c1c[nH]c2ncnc(N[C@@H]3CC[C@@H](CO)OC3)c12- Mol. weight
- 478.94 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4756476 ↗
Also known as
- arq 531
- arq 531
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07194980 | Phase 2 | Dec 31, 2025 | Merck, University of Washington |
| NCT07232589 | Phase 1 | Dec 8, 2025 | Merck |
| NCT06863402 | Phase 2 | Jul 1, 2025 | State University of New York, Buffalo |
| NCT06572618 | Phase 2 | Feb 11, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06442436 | Phase 1 | Jul 24, 2024 | Merck |
| NCT06136559 | Phase 3 | Dec 13, 2023 | Merck |
| NCT06625827 | Phase 1 | Nov 7, 2023 | Merck |
| NCT06688045 | Phase 1 | Oct 30, 2023 | Merck |
| NCT06772818 | Phase 1 | Oct 2, 2023 | Merck |
| NCT06586671 | Phase 1 | Aug 28, 2023 | Merck |
| NCT05947851 | Phase 3 | Aug 8, 2023 | Merck |
| NCT06698016 | Phase 1 | Jul 25, 2023 | Merck |
| NCT06772805 | Phase 1 | Jul 24, 2023 | Merck |
| NCT05673460 | Phase 1 | Feb 13, 2023 | Merck |
| NCT05624554 | Phase 3 | Jan 17, 2023 | Merck |
| NCT05458297 | Phase 2 | Jul 21, 2022 | Merck |
| NCT05347225 | Phase 1 | Jun 9, 2022 | Merck |
| NCT04728893 | Phase 2 | Apr 5, 2021 | Merck |
| NCT03162536 | Phase 1 | Jul 1, 2017 | ArQule |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 16 | 15 | 3 | 2021 |
| ArQule | For profit | 1 | 1 | 1 | 2017 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1